

Donald R Mattison

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/298035/publications.pdf>

Version: 2024-02-01

195
papers

7,579
citations

46918

47
h-index

66788

78
g-index

203
all docs

203
docs citations

203
times ranked

7663
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex Differences in Pharmacokinetics and Pharmacodynamics. <i>Clinical Pharmacokinetics</i> , 2009, 48, 143-157.	1.6	724
2	Environmental Exposures and Adverse Pregnancy Outcomes: A Review of the Science. <i>Reproductive Sciences</i> , 2008, 15, 631-650.	1.1	292
3	Sex Differences in Drug Disposition. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-14.	3.0	224
4	Are We Optimizing Gestational Diabetes Treatment With Glyburide? The Pharmacologic Basis for Better Clinical Practice. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 607-614.	2.3	210
5	Exposure to Hurricane Katrina, Post-traumatic Stress Disorder and Birth Outcomes. <i>American Journal of the Medical Sciences</i> , 2008, 336, 111-115.	0.4	174
6	Chemical contaminants in breast milk and their impacts on children's health: an overview.. <i>Environmental Health Perspectives</i> , 2002, 110, A313-5.	2.8	167
7	Reduction in oocyte number following prenatal exposure to a diet high in galactose. <i>Science</i> , 1981, 214, 1145-1147.	6.0	146
8	The changing epidemiology of multiple births in the United States. <i>Obstetrics and Gynecology</i> , 2003, 101, 129-135.	1.2	131
9	The effects of smoking on fertility from gametogenesis to implantation. <i>Environmental Research</i> , 1982, 28, 410-433.	3.7	129
10	Contribution of birth defects to infant mortality in the United States. <i>Teratology</i> , 2002, 66, S3-S6.	1.8	129
11	Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 203, 571.e1-571.e7.	0.7	126
12	Ending Propylthiouracil-Induced Liver Failure in Children. <i>New England Journal of Medicine</i> , 2009, 360, 1574-1575.	13.9	124
13	Differential Follicle Counts as a Screen for Chemically Induced Ovarian Toxicity in Mice: Results from Continuous Breeding Bioassays. <i>Fundamental and Applied Toxicology</i> , 1997, 39, 1-10.	1.9	119
14	Bisphenol A and indicators of obesity, glucose metabolism/type 2 diabetes and cardiovascular disease: A systematic review of epidemiologic research. <i>Critical Reviews in Toxicology</i> , 2014, 44, 121-150.	1.9	119
15	The role of epoxidation in 4-vinylcyclohexene-induced ovarian toxicity. <i>Toxicology and Applied Pharmacology</i> , 1990, 105, 372-381.	1.3	116
16	Phosphoramidate mustard is responsible for the ovarian toxicity of cyclophosphamide. <i>Toxicology and Applied Pharmacology</i> , 1991, 107, 472-481.	1.3	102
17	Psychotherapeutic Medication Prevalence in Medicaid-Insured Preschoolers. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2007, 17, 195-204.	0.7	99
18	Serum uric acid in relation to endogenous reproductive hormones during the menstrual cycle: findings from the BioCycle study. <i>Human Reproduction</i> , 2013, 28, 1853-1862.	0.4	92

#	ARTICLE	IF	CITATIONS
19	Human placental transport of oxytocin. <i>The Journal of Maternal-fetal Medicine</i> , 1996, 5, 245-255.	0.2	90
20	Do phthalates act as obesogens in humans? A systematic review of the epidemiological literature. <i>Critical Reviews in Toxicology</i> , 2014, 44, 151-175.	1.9	89
21	Morphology of oocyte and follicle destruction by polycyclic aromatic hydrocarbons in mice. <i>Toxicology and Applied Pharmacology</i> , 1980, 53, 249-259.	1.3	86
22	The Effect of Smoking on Oogenesis, Fertilization, and Implantation. <i>Seminars in Reproductive Medicine</i> , 1989, 7, 291-304.	0.5	84
23	Weight of the Evidence Evaluation of Low-Dose Reproductive and Developmental Effects of Bisphenol A. <i>Human and Ecological Risk Assessment (HERA)</i> , 2004, 10, 875-921.	1.7	83
24	Reproductive toxicity of cyclophosphamide in the C57BL/6N mouse: 1. Effects on ovarian structure and function. <i>Reproductive Toxicology</i> , 1992, 6, 411-421.	1.3	82
25	Environmental exposures and development. <i>Current Opinion in Pediatrics</i> , 2010, 22, 208-218.	1.0	79
26	Oocyte destruction by polycyclic aromatic hydrocarbons. <i>American Journal of Industrial Medicine</i> , 1983, 4, 191-202.	1.0	74
27	The Utility of Menstrual Cycle Length as an Indicator of Cumulative Hormonal Exposure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1871-E1879.	1.8	73
28	Menstrual Bleeding Patterns Among Regularly Menstruating Women. <i>American Journal of Epidemiology</i> , 2012, 175, 536-545.	1.6	71
29	Dabigatran, bleeding, and the regulators. <i>BMJ, The</i> , 2014, 349, g4517-g4517.	3.0	70
30	Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, 599.e1-599.e7.	0.7	69
31	Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 204, S84-S88.	0.7	68
32	Clonidine Pharmacokinetics in Pregnancy. <i>Drug Metabolism and Disposition</i> , 2009, 37, 702-705.	1.7	65
33	Comparison of random and serial sections in assessment of ovarian toxicity. <i>Reproductive Toxicology</i> , 1991, 5, 379-383.	1.3	64
34	Galactose inhibition of ovulation in mice. <i>Fertility and Sterility</i> , 1988, 49, 522-526.	0.5	63
35	Reproductive Toxicity: Male and Female Reproductive Systems as Targets for Chemical Injury. <i>Medical Clinics of North America</i> , 1990, 74, 391-411.	1.1	62
36	Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. <i>Biochemical Pharmacology</i> , 2009, 78, 1483-1490.	2.0	62

#	ARTICLE	IF	CITATIONS
37	The Mechanisms of Action of Reproductive Toxicants. <i>Toxicologic Pathology</i> , 1989, 17, 364-376.	0.9	61
38	Propylthiouracil (PTU) Hepatotoxicity in Children and Recommendations for Discontinuation of Use. <i>International Journal of Pediatric Endocrinology (Springer)</i> , 2009, 2009, 1-8.	1.6	59
39	The influence of sporadic anovulation on hormone levels in ovulatory cycles. <i>Human Reproduction</i> , 2013, 28, 1687-1694.	0.4	59
40	Monoclonal antibodies to the major protein of the murine zona pellucida: Effects on fertilization and early development. <i>Developmental Biology</i> , 1984, 104, 49-56.	0.9	58
41	Difference in sensitivity of rat and mouse primordial oocytes to destruction by polycyclic aromatic hydrocarbons. <i>Chemico-Biological Interactions</i> , 1979, 28, 133-137.	1.7	56
42	The mechanisms of action of reproductive toxins. <i>American Journal of Industrial Medicine</i> , 1983, 4, 65-79.	1.0	56
43	Utilizing paramedics for in-patient critical care surge capacity. <i>American Journal of Disaster Medicine</i> , 2010, 5, 163-168.	0.1	56
44	Effect of oocyte number and rate of atresia on the age of menopause. <i>Reproductive Toxicology</i> , 1987, 1, 41-51.	1.3	55
45	Gaps in knowledge in treating pregnant women. <i>Gender Medicine</i> , 2006, 3, 169-182.	1.4	53
46	The use of chlorhexidine to reduce maternal and neonatal mortality and morbidity in low-resource settings. <i>International Journal of Gynecology and Obstetrics</i> , 2007, 97, 89-94.	1.0	53
47	Male-mediated teratogenesis and other reproductive effects: Biologic and epidemiologic findings and a plea for clinical research. <i>Reproductive Toxicology</i> , 1992, 6, 289-292.	1.3	49
48	Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 207, 398.e1-398.e8.	0.7	48
49	Clinical Therapeutics in Pregnancy. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-13.	3.0	46
50	Pharmaco- and toxicokinetics of selected exogenous and endogenous estrogens: A review of the data and identification of knowledge gaps. <i>Critical Reviews in Toxicology</i> , 2014, 44, 696-724.	1.9	44
51	Physiological alterations during pregnancy: Impact on toxicokinetics. <i>Fundamental and Applied Toxicology</i> , 1991, 16, 215-218.	1.9	42
52	Oocyte Destruction by Polycyclic Aromatic Hydrocarbons. <i>American Journal of Industrial Medicine</i> , 1983, 4, 191-202.	1.0	41
53	Structural determinants associated with risk of human developmental toxicity. <i>American Journal of Obstetrics and Gynecology</i> , 1997, 176, 799-806.	0.7	41
54	The Mechanisms of Action of Reproductive Toxins. <i>American Journal of Industrial Medicine</i> , 1983, 4, 65-79.	1.0	40

#	ARTICLE	IF	CITATIONS
55	Beta-Blockers increase the risk of being born small for gestational age or of being institutionalised during infancy. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2014, 121, 1090-1096.	1.1	40
56	Magnetic Resonance Imaging in Prenatal Diagnosis. <i>Clinical Obstetrics and Gynecology</i> , 1988, 31, 353-389.	0.6	39
57	The effect of intraovarian injection of benzo(a)pyrene on primordial oocyte number and ovarian aryl hydrocarbon [benzo(a)pyrene] hydroxylase activity. <i>Toxicology and Applied Pharmacology</i> , 1984, 76, 18-25.	1.3	38
58	Murine oocyte destruction following intraovarian treatment with 3-methylcholanthrene or 7,12-dimethylbenz(a)anthracene: Protection by alpha-naphthoflavone. <i>Teratogenesis, Carcinogenesis, and Mutagenesis</i> , 1985, 5, 463-472.	0.8	37
59	Ovarian toxicity of benzo(a)pyrene and metabolites in mice. <i>Reproductive Toxicology</i> , 1989, 3, 115-125.	1.3	37
60	Effect of albumin on transplacental transfer and distribution of rosiglitazone and glyburide. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2008, 21, 197-207.	0.7	37
61	Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 175, 124-128.	0.5	36
62	The biochemical and genetic characteristics of murine ovarian aryl hydrocarbon (Benzo[a]pyrene) hydroxylase activity and its relationship to primordial oocyte destruction by polycyclic aromatic hydrocarbons. <i>Toxicology and Applied Pharmacology</i> , 1980, 56, 399-408.	1.3	35
63	The effects of chronic methylphenidate administration on operant test battery performance in juvenile rhesus monkeys. <i>Neurotoxicology and Teratology</i> , 2010, 32, 142-151.	1.2	35
64	Pubertal delay in male nonhuman primates (<i>Macaca mulatta</i>) treated with methylphenidate. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 16301-16306.	3.3	34
65	Diagnosis of a viable abdominal pregnancy by magnetic resonance imaging. <i>American Journal of Obstetrics and Gynecology</i> , 1988, 159, 150-151.	0.7	33
66	Simultaneous quantitation of 17 β -hydroxyprogesterone caproate, 17 β -hydroxyprogesterone and progesterone in human plasma using high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS). <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008, 48, 1174-1180.	1.4	33
67	Sex Differences in the Clearance of CYP3A4 Substrates: Exploring Possible Reasons for the Substrate Dependency and Lack of Consensus. <i>Current Drug Metabolism</i> , 2012, 13, 778-786.	0.7	33
68	Effects of toxic substances on female reproduction. <i>Environmental Health Perspectives</i> , 1983, 48, 43-52.	2.8	32
69	Hepatobiliary Disposition of 17-OHPC and Taurocholate in Fetal Human Hepatocytes: A Comparison with Adult Human Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2013, 41, 296-304.	1.7	32
70	Degeneration of mouse oocytes in response to polycyclic aromatic hydrocarbons. <i>The Anatomical Record</i> , 1979, 193, 863-881.	2.3	31
71	Linking Drugs to Obscure Illnesses: Lessons from Pure Red Cell Aplasia, Nephrogenic Systemic Fibrosis, and Reye's Syndrome. A Report From the Southern Network on Adverse Reactions (SONAR). <i>Journal of General Internal Medicine</i> , 2012, 27, 1697-1703.	1.3	31
72	Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial. <i>BMC Pregnancy and Childbirth</i> , 2015, 15, 59.	0.9	31

#	ARTICLE	IF	CITATIONS
73	Transplacental transfer and metabolism of 17 β -hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology, 2008, 199, 169.e1-169.e5.	0.7	30
74	Evaluation of Macaca mulatta as a model for genotoxicity studies. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2009, 673, 21-28.	0.9	30
75	Cancer Cluster Investigations: Review of the Past and Proposals for the Future. International Journal of Environmental Research and Public Health, 2014, 11, 1479-1499.	1.2	30
76	Cyclosporine A: Review of genotoxicity and potential for adverse human reproductive and developmental effects. Mutation Research - Reviews in Genetic Toxicology, 1994, 317, 163-173.	3.0	29
77	Identification of Enzymes Involved in the Metabolism of 17 β -Hydroxyprogesterone Caproate: An Effective Agent for Prevention of Preterm Birth. Drug Metabolism and Disposition, 2008, 36, 1896-1902.	1.7	29
78	Using Systematic Reviews and Meta-Analyses to Support Regulatory Decision Making for Neurotoxicants: Lessons Learned from a Case Study of PCBs. Environmental Health Perspectives, 2010, 118, 727-734.	2.8	29
79	Genetic differences in mouse ovarian metabolism of benzo[a]pyrene and oocyte toxicity. Biochemical Pharmacology, 1977, 26, 909-912.	2.0	28
80	The effect of benzo(a)pyrene on murine ovarian and corpora lutea volumes. American Journal of Obstetrics and Gynecology, 1992, 166, 1535-1541.	0.7	28
81	Methylphenidate and Amphetamine Do Not Induce Cytogenetic Damage in Lymphocytes of Children With ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2008, 47, 1375-1383.	0.3	28
82	Bone mineral density and blood metals in premenopausal women. Environmental Research, 2013, 120, 76-81.	3.7	26
83	The application of PBPK models in estimating human brain tissue manganese concentrations. NeuroToxicology, 2017, 58, 226-237.	1.4	26
84	Benzo(a)pyrene inhibits ovulation in C57BL/6N mice. The Anatomical Record, 1985, 212, 268-276.	2.3	25
85	The threshold dose question in teratogenesis. Teratology, 1988, 38, 389-391.	1.8	25
86	Neural tube defect-specific infant mortality in the United States. Teratology, 2002, 66, S17-S22.	1.8	25
87	Pharmacokinetics, dose range, and mutagenicity studies of methylphenidate hydrochloride in B6C3F1 mice. Environmental and Molecular Mutagenesis, 2008, 49, 585-593.	0.9	25
88	Metabolism of 17 β -hydroxyprogesterone caproate by hepatic and placental microsomes of human and baboons. Biochemical Pharmacology, 2008, 75, 1848-1857.	2.0	25
89	The status of pharmacometrics in pregnancy: highlights from the 3 rd American conference on pharmacometrics. British Journal of Clinical Pharmacology, 2012, 74, 932-939.	1.1	25
90	Structural determinants of developmental toxicity in hamsters. , 1999, 60, 190-205.		24

#	ARTICLE	IF	CITATIONS
91	Experimental and clinical studies on the reproductive toxicology of 2,3,7,8-tetrachlorodibenzo-p-dioxin. <i>American Journal of Industrial Medicine</i> , 1987, 11, 131-144.	1.0	23
92	The genetic toxicology of methylphenidate hydrochloride in non-human primates. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2009, 673, 59-66.	0.9	23
93	Differences in benzo(a)pyrene metabolic profile in rat and mouse ovary. <i>Biochemical Pharmacology</i> , 1979, 28, 2101-2104.	2.0	22
94	Criteria for identifying and listing substances known to cause developmental toxicity under California's proposition 65. <i>Reproductive Toxicology</i> , 1989, 3, 3-12.	1.3	22
95	Morphometric assessment of the murine ovarian toxicity of 7,12-dimethylbenz(a)anthracene. <i>Reproductive Toxicology</i> , 1992, 6, 137-141.	1.3	22
96	The Heart of the Matter on Breastmilk and Environmental Chemicals: Essential Points for Healthcare Providers and New Parents. <i>Breastfeeding Medicine</i> , 2008, 3, 251-259.	0.8	22
97	Resistance of the Male Gonad to a High Galactose Diet. <i>Pediatric Research</i> , 1984, 18, 345-348.	1.1	21
98	Metabolism of 17 β -Hydroxyprogesterone Caproate, an Agent for Preventing Preterm Birth, by Fetal Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2010, 38, 723-727.	1.7	21
99	Trends in using beta-blockers and methyl dopa for hypertensive disorders during pregnancy in a Canadian population. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2013, 171, 281-285.	0.5	21
100	Development of a Physiologically Based Model to Describe the Pharmacokinetics of Methylphenidate in Juvenile and Adult Humans and Nonhuman Primates. <i>PLoS ONE</i> , 2014, 9, e106101.	1.1	21
101	Structural Determinants of Developmental Toxicity ¹ . <i>Risk Analysis</i> , 1994, 14, 649-657.	1.5	20
102	Drugs and Medicines in Pregnancy: The Placental Disposition of Opioids. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 797-803.	0.9	20
103	Transport and metabolism of dexamethasone in the dually perfused human placenta. <i>Reproductive Toxicology</i> , 1988, 2, 37-43.	1.3	19
104	Transdermal Drug Absorption During Pregnancy. <i>Clinical Obstetrics and Gynecology</i> , 1990, 33, 718-727.	0.6	19
105	Drug development for use during pregnancy: impact of the placenta. <i>Expert Review of Obstetrics and Gynecology</i> , 2010, 5, 437-454.	0.4	19
106	Modeling U-shaped dose-response curves for manganese using categorical regression. <i>NeuroToxicology</i> , 2017, 58, 217-225.	1.4	19
107	Summary of the Workshop on Issues in Risk Assessment: Quantitative Methods for Developmental Toxicology. <i>Risk Analysis</i> , 1994, 14, 595-604.	1.5	18
108	Severity scoring of manganese health effects for categorical regression. <i>NeuroToxicology</i> , 2017, 58, 203-216.	1.4	18

#	ARTICLE	IF	CITATIONS
109	Critical review of the association between perineal use of talc powder and risk of ovarian cancer. <i>Reproductive Toxicology</i> , 2019, 90, 88-101.	1.3	18
110	Mechanisms of regulation of rat ovarian 7,12-dimethylbenz[a]anthracene hydroxylase. <i>Chemico-Biological Interactions</i> , 1987, 63, 15-27.	1.7	17
111	A matrix for bridging the epidemiology and risk assessment gap. <i>Global Epidemiology</i> , 2019, 1, 100005.	0.6	17
112	Eliciting principles of hazard identification from experts. <i>Teratology</i> , 1990, 42, 521-533.	1.8	16
113	Sites of female reproductive vulnerability: Implications for testing and risk assessment. <i>Reproductive Toxicology</i> , 1993, 7, 53-62.	1.3	16
114	A proposal to facilitate weight-of-evidence assessments: Harmonization of Neurodevelopmental Environmental Epidemiology Studies (HONEES). <i>Neurotoxicology and Teratology</i> , 2011, 33, 354-359.	1.2	16
115	Criteria for identifying and listing substances known to cause reproductive toxicity under California's proposition 65. <i>Reproductive Toxicology</i> , 1990, 4, 163-175.	1.3	15
116	Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000-2016. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 227-235.	0.8	15
117	Impact of cocaine on human placental function using an in vitro perfusion system. <i>Journal of Pharmacological and Toxicological Methods</i> , 1995, 33, 213-219.	0.3	14
118	Magnetic Resonance Imaging: A Noninvasive Tool for Fetal and Placental Physiology. <i>Biology of Reproduction</i> , 1988, 38, 39-49.	1.2	13
119	Protecting reproductive and developmental health under proposition 65 - public health approaches to knowledge, imperfect knowledge, and the absence of knowledge. <i>Reproductive Toxicology</i> , 1992, 6, 1-7.	1.3	13
120	Human decidual cell Toll-like receptor signaling in response to endotoxin: The effect of progestins. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 198, 119.e1-119.e4.	0.7	13
121	Adolescents in Clinical Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 655-659.	2.3	13
122	Systematic review and meta-analysis of adverse cardiovascular events associated with proton pump inhibitors used alone or in combination with antiplatelet agents. <i>Critical Reviews in Toxicology</i> , 2019, 49, 215-261.	1.9	13
123	Biological Monitoring of the Human Placenta. , 1988, , 567-602.		12
124	Methylphenidate and chromosome damage. <i>Cancer Letters</i> , 2008, 260, 216-218.	3.2	12
125	Advancing the Selection of Neurodevelopmental Measures in Epidemiological Studies of Environmental Chemical Exposure and Health Effects. <i>International Journal of Environmental Research and Public Health</i> , 2010, 7, 229-268.	1.2	12
126	Magnetic resonance imaging of monkey placenta with manganese enhancement. <i>American Journal of Obstetrics and Gynecology</i> , 1987, 157, 185-189.	0.7	11

#	ARTICLE	IF	CITATIONS
127	Workshop on Risk Assessment in Reproductive and Developmental Toxicology: Addressing the Assumptions and Identifying the Research Needs. <i>Regulatory Toxicology and Pharmacology</i> , 1989, 10, 110-122.	1.3	11
128	Energy charge monitoring via magnetic resonance spectroscopy ³¹ P in the perfused human placenta: effects of cadmium, dinitrophenol and Iodoacetate. <i>Placenta</i> , 1996, 17, 495-506.	0.7	11
129	The Unnecessary Epidemic of Folic Acid-Preventable Spina Bifida and Anencephaly. <i>Pediatrics</i> , 2001, 108, 1048-1050.	1.0	11
130	Asthma-related medication use among children in the United States. <i>Annals of Allergy, Asthma and Immunology</i> , 2008, 100, 222-229.	0.5	11
131	Glyburide Metabolism by Placentas of Healthy and Gestational Diabetics. <i>American Journal of Perinatology</i> , 2008, 25, 169-174.	0.6	11
132	Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations. <i>Vaccines</i> , 2022, 10, 722.	2.1	11
133	Gonadotropin-dependent metabolism of 7,12-dimethylbenz(a)anthracene in the ovary of rhesus monkey. <i>Biochemical Pharmacology</i> , 1989, 38, 1869-1872.	2.0	9
134	Differential Follicle Counts as a Screen for Chemically Induced Ovarian Toxicity in Mice: Results from Continuous Breeding Bioassays. <i>Toxicological Sciences</i> , 1997, 39, 1-10.	1.4	9
135	Prenatal Programming and Toxicity II (PPTOX II): Role of environmental stressors in the developmental origins of disease. <i>Reproductive Toxicology</i> , 2011, 31, 271.	1.3	9
136	Reproductive and Developmental Toxicity of Metals: Female Reproductive System. , 1983, , 41-91.		8
137	Human Placental Transport of Oxytocin. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 1996, 5, 245-255.	0.7	8
138	Studying the antiemetic effect of vitamin B6 for morning sickness: Pyridoxine and pyridoxal are prodrugs. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1429-1433.	1.0	8
139	Improving Concordance in Environmental Epidemiology: A Three-Part Proposal. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , 2015, 18, 105-120.	2.9	8
140	Female reproduction. <i>American Journal of Industrial Medicine</i> , 1983, 4, 17-30.	1.0	8
141	Improving Predictive Modeling in Pediatric Drug Development: Pharmacokinetics, Pharmacodynamics, and Mechanistic Modeling. <i>Annals of the New York Academy of Sciences</i> , 2005, 1053, 505-518.	1.8	8
142	Safety and effectiveness of <sc>NMDA</sc> receptor antagonists for depression: A multidisciplinary review. <i>Pharmacotherapy</i> , 2022, 42, 567-579.	1.2	8
143	Development and validation of a high-performance liquid chromatography-mass spectrometric assay for the determination of 17 β -hydroxyprogesterone caproate (17-OHPC) in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 856, 141-147.	1.2	7
144	A Categorical Structure-Activity Relationship Analysis of the Developmental Toxicity of Antithyroid Drugs. <i>International Journal of Pediatric Endocrinology (Springer)</i> , 2009, 2009, 1-7.	1.6	7

#	ARTICLE	IF	CITATIONS
145	Effectiveness of doxylamine-pyridoxine for morning sickness. American Journal of Obstetrics and Gynecology, 2016, 214, 664-666.	0.7	7
146	Reproductive and developmental toxicology. , 1985, , 215-224.		7
147	Human developmental toxicity and mutagenesis. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1998, 422, 347-350.	0.4	6
148	A Tale of Two Citizens: A State Attorney General and a Hematologist Facilitate Translation of Research Into US Food and Drug Administration Actionsâ€”A SONAR Report. Journal of Oncology Practice, 2012, 8, e158-e167.	2.5	6
149	The genetic toxicity of methylphenidate: a review of the current literature. Journal of Applied Toxicology, 2012, 32, 756-764.	1.4	6
150	Association of treatments for acute appendicitis with pregnancy outcomes in the United States from 2000 to 2016: Results from a multi-level analysis. PLoS ONE, 2021, 16, e0260991.	1.1	6
151	The goal: Safety and equality. American Journal of Industrial Medicine, 1992, 21, 463-465.	1.0	5
152	A Reproductive Hazards Research Agenda for the 1990s. Environmental Health Perspectives, 1993, 101, 175.	2.8	5
153	EPA dioxin reassessment. Science, 1994, 266, 1628-1629.	6.0	5
154	Continuous pO ₂ Monitoring during Dual Perfusion of the Term Human Placenta in vitro. Gynecologic and Obstetric Investigation, 1995, 39, 28-33.	0.7	5
155	Modeling Adverse Environmental Impacts on the Reproductive System. Journal of Women's Health, 1999, 8, 217-226.	0.9	5
156	Evaluation of mutagenic mode of action in Big Blue mice fed methylphenidate for 24 weeks. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2009, 680, 43-48.	0.9	5
157	Demonstration of early efficacy results of the delayed-release combination of doxylamine-pyridoxine for the treatment of nausea and vomiting of pregnancy. BMC Pregnancy and Childbirth, 2016, 16, 371.	0.9	5
158	Risk of Adverse Cardiovascular Events Following a Myocardial Infarction in Patients Receiving Combined Clopidogrel and Proton Pump Inhibitor Treatment: A Nested Caseâ€”Control Study. Drugs - Real World Outcomes, 2020, 7, 191-203.	0.7	5
159	Ovarian Toxicity: Effects on Sexual Maturation, Reproduction and Menopause. , 1983, , 317-342.		4
160	Highlights from the United States Food and Drug Administration's public workshop on the development of animal models of pregnancy to address medical countermeasures in an "at-risk" population of pregnant women: Influenza as a case study. Birth Defects Research Part A: Clinical and Molecular Teratology, 2014, 100, 806-810.	1.6	4
161	Systemic quinolones and risk of acute liver failure III: A nested caseâ€”control study using a US electronic health records database. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2307-2314.	1.4	4
162	Systemic quinolones and risk of retinal detachment I: analysis of data from the US FDA adverse event reporting system. Expert Opinion on Drug Safety, 2022, 21, 269-276.	1.0	4

#	ARTICLE	IF	CITATIONS
163	Physiological Alterations during Pregnancy: Impact on Toxicokinetics. <i>Toxicological Sciences</i> , 1991, 16, 215-218.	1.4	3
164	Temporal Issues in Reproductive Risk Assessment. <i>Inhalation Toxicology</i> , 1995, 7, 837-862.	0.8	3
165	Selected Proceedings of the NICHD/FDA newborn drug development initiative: Part II. <i>Clinical Therapeutics</i> , 2006, 28, 1337-1341.	1.1	3
166	Pharmacokinetics of oseltamivir phosphate and oseltamivir carboxylate in non-pregnant and pregnant rhesus monkeys. <i>Regulatory Toxicology and Pharmacology</i> , 2020, 112, 104569.	1.3	3
167	Analgesics for the Treatment of Pain in Children. <i>New England Journal of Medicine</i> , 2003, 348, 959-960.	13.9	2
168	363: Identification of the major human hepatic and placental enzymes responsible for the metabolism of glyburide. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, S111.	0.7	2
169	Ovarian Morphometric Changes following Cyclophosphamide Treatment. , 1989, , 427-431.		2
170	Systemic quinolones and risk of retinal detachment III: a nested caseâ€“control study using a US electronic health records database. <i>European Journal of Clinical Pharmacology</i> , 2022, , 1.	0.8	2
171	Introduction: Biological Markers of Male Reproductive Toxicology. <i>Environmental Health Perspectives</i> , 1987, 74, 11.	2.8	1
172	Making Progress for How Medicines Are Used in Children. <i>JAMA Pediatrics</i> , 2007, 161, 916.	3.6	1
173	53: Are we guessing glyburide dosage in the treatment of gestational diabetes (GDM)? The pharmacological evidence for better clinical practice. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, S25.	0.7	1
174	Improving Pediatric Drug Development: Challenges, Opportunities and Lessons Learned. <i>Frontiers in Pharmacology</i> , 2010, 1, .	1.6	1
175	Using systematic reviews and meta-analyses to support regulatory decision making for neurotoxicants: lessons learned from a case study of PCBs. <i>Ciencia E Saude Coletiva</i> , 2011, 16, 3207-3220.	0.1	1
176	Prenatal Programming and Toxicity II (PPTOX II): Role of Environmental Stressors in the Developmental Origins of Disease. <i>Journal of Developmental Origins of Health and Disease</i> , 2011, 2, 2-2.	0.7	1
177	Antidepressant treatment of Medicaid-insured youth with a cancer diagnosis. <i>Journal of Pharmaceutical Health Services Research</i> , 2012, 3, 109-114.	0.3	1
178	Direct oral anticoagulants and oesophageal disorders: a pharmacovigilance analysis. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1045-1047.	0.8	1
179	Preface: Reproductive toxicology. <i>American Journal of Industrial Medicine</i> , 1983, 4, 1-2.	1.0	1
180	OVARIAN ARYL HYDROCARBON HYDROXYLASE ACTIVITY AND OOCYTE DESTRUCTION. , 1980, , 1219-1222.		1

#	ARTICLE	IF	CITATIONS
181	Magnetic resonance imaging (MRI) of the circulation and the heterogeneous distribution of manganese chloride compared with the uptake of ⁵⁴ Mn in the dually-perfused isolated human placental lobule. <i>Placenta</i> , 1986, 7, 446-447.	0.7	0
182	Quantitative Risk Assessment for Paternally-Mediated Developmental Toxicity. , 1994, , 261-284.		0
183	Introduction Session IV: Implications of new approaches for improved risk assessment for developmental abnormalities. <i>Reproductive Toxicology</i> , 1997, 11, 437-441.	1.3	0
184	22 Statistical methods for reproductive risk assessment. <i>Handbook of Statistics</i> , 2000, , 649-671.	0.4	0
185	Endocrine and Reproductive Disorders. , 2005, , 609-643.		0
186	113: Metabolism of 17-hydroxyprogesterone caproate by the dually perfused human placental lobule. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, S45.	0.7	0
187	124: Metabolism of 17-hydroxyprogesterone caproate by human hepatic and placental microsomes. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, S48.	0.7	0
188	Response to Geraghty et al.. <i>Breastfeeding Medicine</i> , 2009, 4, 127-127.	0.8	0
189	Letter to the Editor. <i>Journal of Attention Disorders</i> , 2010, 14, 203-204.	1.5	0
190	Treating the Placenta. , 2013, , 73-87.		0
191	Compounded bioidentical hormone products, a path forward. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2021, , .	0.7	0
192	Treating the placenta. , 2022, , 79-92.		0
193	What Evidence is Required to Identify a Chemical as a Reproductive Hazard?. , 1984, , 153-165.		0
194	Hepatic Bioactivation of 4-Vinylcyclohexene to Ovotoxic Epoxides. <i>Advances in Experimental Medicine and Biology</i> , 1991, 283, 465-470.	0.8	0
195	Assessing Reproductive Risks with Biological Markers. , 1993, , 137-158.		0